Cancer Cells and Metastasis
Cancer Cells and Metastasis is a research topic within Oncology. Science Explorer counts 47k research works in it since 1950. 24.3% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the role of cancer stem cells, epithelial-mesenchymal transition, and the tumor microenvironment in tumor metastasis, drug resistance, and cell plasticity. It explores the identification, regulation, and behavior of cancer stem cells, as well as their interactions with the microenvironment and implications for metastatic colonization. Additionally, it delves into the use of organoid models to study cancer stem cells and tumor progression.
- Cancer Stem Cells
- Tumor Metastasis
- Epithelial-Mesenchymal Transition
- Stem Cell Niches
- Tumorigenic Cells
- Metastatic Colonization
- Microenvironment Regulation
- Drug Resistance
- Cell Plasticity
- Organoid Models
- Research works
- 47k fractional, since 1950
- In the world top 10%
- 12k per year above
- Top-10% rate
- 24.3% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +13% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Cancer Cells and Metastasis research?
By volume, China and the United States publish the most (2.4k and 2.1k works in 2022–2025).
By volume, 2022–2025
- 1 China 2.4k works
- 2 United States 2.1k works
- 3 Japan 445 works
- 4 India 423 works
- 5 Germany 398 works
- 6 South Korea 292 works
- 7 Italy 286 works
- 8 United Kingdom 280 works
- 9 France 225 works
- 10 Spain 186 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Cancer Cells and Metastasis research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Cancer Cells and Metastasis research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and Sun Yat-sen University.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer CenterUnited States 66 works
- 2 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 46 works
- 3 Sun Yat-sen UniversityChina 44 works
- 4 University of MichiganUnited States 42 works
- 5 Shanghai Jiao Tong UniversityChina 37 works
- 6 Sichuan UniversityChina 33 works
- 7 Nanjing Medical UniversityChina 27 works
- 8 Harvard UniversityUnited States 26 works
- 9 Cornell UniversityUnited States 26 works
- 10 Huazhong University of Science and TechnologyChina 26 works
Who are the leading researchers in Cancer Cells and Metastasis?
The most-cited researchers publishing on Cancer Cells and Metastasis include Douglas Hanahan, Robert A. Weinberg and Bert Vogelstein.
- 1 Douglas Hanahan United States 10k citations
- 2 Robert A. Weinberg United States 8.3k citations
- 3 Bert Vogelstein United States 7.1k citations
- 4 Charles M. Perou United States 4.2k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Cancer Cells and Metastasis research done?
The largest centres of Cancer Cells and Metastasis research in 2022–2025 are Beijing (China), Shanghai (China), Guangzhou (China) and Seoul (South Korea).
Largest cities, 2022–2025
Where is the best place to study Cancer Cells and Metastasis?
Among universities, judged by research, Oncode Institute, Shanghai Medical College of Fudan University and China Medical University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Oncode InstituteNetherlands | 75.6 | 45.4% | 44.8× | 12 | +305.3% |
| 2 | Shanghai Medical College of Fudan UniversityChina | 61.2 | 46.8% | 13.3× | 10 | +40.1% |
| 3 | China Medical UniversityChina | 59.7 | 40.6% | 8.9× | 25 | -8.7% |
| 4 | Nanjing University of Chinese MedicineChina | 56.8 | 46.2% | 6.0× | 13 | +110.5% |
| 5 | Nanjing Medical UniversityChina | 53.1 | 35.6% | 6.0× | 27 | +51.7% |
| 6 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 53.0 | 29.0% | 5.3× | 46 | +61.4% |
| 7 | Sichuan UniversityChina | 52.0 | 43.6% | 2.2× | 33 | +77.0% |
| 8 | ETH ZurichSwitzerland | 49.2 | 49.5% | 1.7× | 10 | +102.4% |
| 9 | Guangzhou Medical UniversityChina | 49.1 | 32.5% | 6.3× | 15 | +86.5% |
| 10 | Dalian Medical UniversityChina | 48.1 | 24.7% | 8.6× | 14 | +74.5% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Cancer Cells and Metastasis research growing?
Output in 2018–2022 was 13% higher than in 2013–2017, peaking in 2022. The fastest-growing topics are Cancer Cells and Metastasis.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.